NANOMUG S.R.L.

Bacterial biofilms are among the most medically significant and therapeutically challenging biological structures that modern medicine confronts. When bacteria aggregate and encase themselves in a protective extracellular matrix — as they do in biofilms — they become dramatically more resistant to conventional antibiotic treatment, to immune system clearance, and to virtually every other defence mechanism that the body and clinical medicine deploy against infection. Biofilm-associated infections underpin a substantial proportion of chronic infectious disease burden, medical device-related complications, and treatment failures in hospitals globally. NanoMuG has positioned itself at the frontier of addressing this challenge through nanotechnology. The company develops nanotechnology-based drug delivery systems specifically engineered to interact with and disrupt biofilm structures in ways that conventional therapeutic approaches cannot achieve. Nanoparticles designed at the right scale and with the appropriate surface chemistry can penetrate the protective matrix of biofilms, reach the bacterial communities embedded within, and deliver therapeutic payloads with a precision and efficacy that bulk antibiotic administration fundamentally cannot match. This is nanomedicine applied to one of the most resistant targets in clinical microbiology. NanoMuG's collaboration with SCELSE — the Singapore Centre for Environmental Life Sciences Engineering, one of the world's leading research centres dedicated to biofilm science — signals both the scientific seriousness of the company's approach and its international ambitions. This is not incremental product development but frontier research with a clear and ambitious translational pathway. Beyond the biofilm focus, NanoMuG's platform has broad applicability across three therapeutic domains that the company has identified as strategic priorities: oncology, infectious disease, and mucosal health applications. Each represents a significant area of unmet clinical need and a substantial commercial opportunity, and the modular nature of the nanotechnology platform — its capacity to be adapted for different therapeutic payloads, different target tissues, and different delivery routes — is a major advantage as the company progresses through its development pipeline. NanoMuG's stated vision is to become the preferred strategic partner in the pharmaceutical industry for innovative, high-impact nanomedical solutions in oncology, infectious disease, and mucosal health. The collaboration with SCELSE positions the company at the intersection of biofilm science and nanotechnology — a combination that has the potential to redefine how some of the most treatment-resistant infections are approached clinically. The growth strategy centres on partnerships and ecosystem development with research institutions, pharmaceutical companies, and clinical development organisations capable of accelerating the translation of NanoMuG's nanotechnology platform into clinical and commercial reality on a global scale.